Suven Life Sciences (Suven) is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) at 8th Clinical Trials on Alzheimer’s Disease (CTAD) conference held during November 5-7, 2015 at Barcelona, Spain. Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges.
The goal of 8th Clinical Trials on Alzheimer’s Disease (CTAD) conference is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. During CTAD- 2015 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore potential partnering and out licensing of the clinical candidates SUVN-502, SUVN-G3031, SUVN-D4010 and pre-clinical candidate SUVN-911.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
